Botanix Pharmaceuticals

Home
Australia
West Perth, WA
Botanix Pharmaceuticals

Botanix Pharmaceuticals is a dermatology company developing novel treatments for common skin diseases and infections.

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has launched Sofdra, its FDA-approved product, in the United States.

21/04/2026

📆 Quarterly Update Webinar | Registration Open

Join our executive team for the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report Webinar on 29 April at 10.30 am AEST / 8.30 am AWST for an important update.

Pre-register: https://botanixpharma.zoom.us/webinar/register/WN_6xiTQOIzTuyb6726lE5yQQ #/registration

$BOT

26/02/2026

Half Year Webinar 3 March | Registration Open

Join our executive team for the Company’s Half Year Financial Report Webinar on 3 March at 11 am AEDT (Sydney/Melbourne)/8 am AWST (Perth) for an important update.

Pre-register here: https://us06web.zoom.us/webinar/register/WN_8BQalV5cRuaR5_c-S5Dh_g

$BOT

26/01/2026

Quarterly Activity and 4C Quarterly Cash Flow Reports for Q2 FY26 have been released. Quarter over quarter, total prescriptions shipped for Sofdra® (sofpironium) grew 24% to 25,351, and net revenue increased 28% to $9.1 million.

Read the reports here: https://bit.ly/3Zwa1cn

$BOT

21/01/2026

📆 Quarterly Update Webinar | Registration Open

Join our executive team for the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report Webinar on 27 January at 10.30 am AEDT / 7.30 am AWST for an important update.

Pre-register here: https://us06web.zoom.us/webinar/register/WN_XOM7QZfiRhip3nJ8mwGugg #/registration

$BOT

20/11/2025

AGM Chairman’s Address is now available

Botanix thanks valued shareholders and other significant contributors to the success of Sofdra (sofpironium) in the Chairman’s Address presented at the Annual General Meeting held 20 November.

View ASX Release: https://bit.ly/3LH4k83

$BOT

10/11/2025

Sofdra posters presented at dermatology conferences

Three Sofdra scientific posters were accepted and exhibited at leading dermatology continuing medical education (CME) conferences. CME is a trusted source of information for dermatologists.

🔗 Read the full story: https://bit.ly/4oZmdgv

$BOT

03/11/2025

Botanix Supports Hyperhidrosis Awareness Month

Throughout November, Botanix will introduce new materials in dermatology offices to raise awareness of excessive underarm sweating and Sofdra® (sofpironium).

Click to read the full story: https://bit.ly/4oouGtU

$BOT

21/10/2025

Botanix Presents at Canaccord Conference

Chief Executive Officer Dr Howie McKibbon will present to institutional investors at today’s Canaccord Drug and Device Healthcare Conference in Noosa. For the balance of the week, Canaccord Genuity will host a Botanix investor roadshow.

View ASX Release: https://bit.ly/4o1X4lq

$BOT

19/10/2025

🔸 Botanix Releases Quarterly Reports 🔸

The Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q1 FY2026 have been released. Quarter over quarter, total prescriptions for Sofdra® (sofpironium) increased 50% to 20,418 as operating cash outflow decreased 54% to $13.1 million. Net revenue was $7.1 million.

🔗 View Reports: http://bit.ly/3WNLDS8

$BOT

16/10/2025

📆 Quarterly Update Webinar | Registration Open

Join our executive team for the Company’s Quarterly Activity Report and 4C Quarterly Cash Flow Report Webinar on Monday 20 October at 11.00 am AEDT / 8.00 am AWST for an important update.

Pre-register 👉 https://us06web.zoom.us/webinar/register/WN_-oGtp6viSHG5NwrKmitAsw

$BOT

04/09/2025

🔸 ECCLOCK® approved in South Korea 🔸

Botanix announced that Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea. Dongwha is a sublicensee of Botanix’s Japanese partner, Kaken Pharmaceutical Co. Ltd.

31/08/2025

🔸 Botanix Releases Annual Report 🔸

The Annual Report for FY2025 has been released. At year end, Botanix held $64.9 million cash and $15.3 million in undrawn debt. Operating costs are stable with no inventory purchases anticipated in 1H FY2026, and revenue is expected to increase quarterly. The Company is well funded to achieve profitability.

View Report 👉 https://bit.ly/BOT_Annual_Report

$BOT

Address

Suite 3 41 – 47 Colin Street
West Perth, WA
6005

Telephone

+61865552945

Website

https://www.botanixpharma.com/

Alerts

Be the first to know and let us send you an email when Botanix Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Botanix Pharmaceuticals:

Shortcuts

Want your practice to be the top-listed Clinic in West Perth?